ADEKA (4401) FY2026 Q3 Earnings Report

Quick View

Executive Summary

The company posted higher earnings despite largely flat revenue. Although revenue growth was limited, net income continued to trend upward. Revenue was ¥2967.9B (+0.1% YoY), while Operating Income was ¥293.1B (-2.6% YoY). Meanwhile, Ordinary Income increased to ¥303.9B (+2.4% YoY) and consolidated Net Income rose to ¥215.7B (+3.3% YoY), due to an improvement in non-operating income and expenses. The decline in Operating Income was primarily attributable to lower revenue and earnings in the core Chemicals Business, which was partially offset by higher revenue and earnings in the Life Sciences Business.

Factors Affecting Performance

【Revenue】Revenue was ¥2967.9B, essentially flat at +0.1% YoY. By segment, the Chemicals Business reported lower revenue of ¥1590.7B (53.6% of total, -5.1% YoY), while the Food Business also posted a slight decline to ¥627.6B (-0.5% YoY). In contrast, the Life Sciences Business grew significantly to ¥703.6B (+14.6% YoY), offsetting the revenue decline in the Chemicals Business.

【Profit and Loss】Operating Income was ¥293.1B (-2.6% YoY), and the Operating Margin declined to 9.9% from 10.2% in the same period of the previous year. Although the gross margin improved to 28.6% YoY, selling, general and administrative expenses increased to ¥554.5B (+2.8% YoY), outpacing revenue growth and putting pressure on Operating Income. By segment, Chemicals Business segment profit declined to ¥199.6B (-12.2% YoY; margin 12.5%), making it the primary cause of the overall earnings decline. Meanwhile, the Life Sciences Business provided significant support, with profit rising to ¥50.5B (+66.4% YoY; margin 7.2%). Non-operating income and expenses improved as total interest income, foreign exchange gains, and dividend income of ¥62.5B exceeded interest expense and other items of ¥51.6B, resulting in Ordinary Income of ¥303.9B (+2.4% YoY). Extraordinary income and expenses resulted in a net loss of ¥7.9B, including litigation settlement costs of ¥10.3B, slightly reducing Net Income as a temporary factor. In conclusion, the company recorded lower Operating Income but higher Ordinary Income and Net Income amid only marginal revenue growth; in substance, the results were close to a combination of higher revenue and lower operating earnings.

Segment Analysis

The Chemicals Business generated revenue of ¥1590.7B (53.6% of total) and segment profit of ¥199.6B (margin 12.5%), representing declines of 5.1% in revenue and 12.2% in profit YoY. Its contribution to consolidated Operating Income was approximately 68%, the largest among the segments, making it the primary driver of company-wide earnings fluctuations. The Food Business posted revenue of ¥627.6B (-0.5% YoY) and profit of ¥35.8B (-4.7% YoY; margin 5.7%), representing slight declines in both revenue and profit. The Life Sciences Business was the only segment to achieve both revenue and profit growth, with revenue of ¥703.6B (+14.6% YoY) and profit of ¥50.5B (+66.4% YoY; margin 7.2%); its margin also improved from 5.0% in the previous year to 7.2%. The business composition clearly indicates that the high degree of reliance on the Chemicals Business, together with growth and improved profitability in the Life Sciences Business, determines the quality of company-wide performance.

Key Financial Indicators

【Profitability】The Operating Margin declined to 9.9% from 10.2% in the same period of the previous year, while the gross margin improved slightly to 28.6% (28.4% in the previous year), indicating a trade-off between cost efficiency improvements and higher selling, general and administrative expenses. The Net Profit Margin, based on Net Income attributable to owners of the parent, was 6.7%, broadly in line with the same period of the previous year.【Cash Quality】Comprehensive Income was ¥363.1B, substantially exceeding Net Income of ¥215.7B, with valuation-related factors such as foreign currency translation adjustments of ¥80.8B and valuation differences on securities of ¥56.5B contributing to the result. This divergence indicates that factors other than the business’s underlying earnings power are boosting Comprehensive Income.【Investment Efficiency】Annualized ROE was 7.9%, remaining at a level determined by the combination of the Net Profit Margin and asset turnover. Given the low financial leverage, restoring core operating margins will be an issue in improving capital efficiency.【Financial Soundness】The Equity Ratio was high at 65.3%, while current assets of ¥3543.8B substantially exceeded current liabilities of ¥1233.2B. Cash and deposits of ¥1028.8B exceeded interest-bearing debt, resulting in a net cash position and a conservative financial foundation.

Cash Flow Analysis

As the report does not disclose figures for each category of the cash flow statement, cash trends are assessed based on changes in the balance sheet. Cash and deposits were ¥1028.8B, down from ¥1101.2B in the same period of the previous year. Meanwhile, investment securities increased 16.1% YoY to ¥496.9B, and property, plant and equipment also expanded to ¥1300.6B. Inventories increased 22.7% YoY to ¥754.5B, indicating a growing amount of funds tied up in inventory. On the other hand, accounts payable increased 15.2% to ¥693.8B, partially offsetting the cash burden from higher trade payables. The deduction for treasury stock expanded from ¥46.7B in the same period of the previous year to ¥142.3B, indicating increased cash outflows to external parties through shareholder returns. Overall, while the company is simultaneously investing funds in operating assets and investment securities and providing shareholder returns, the funds tied up in working capital due to higher inventories warrant attention from a cash-efficiency perspective.

Quality of Earnings

Of the ¥62.5B in non-operating income relative to Ordinary Income of ¥303.9B, foreign exchange gains of ¥15.1B and dividend income of ¥9.2B depend on market conditions and held assets and should be evaluated separately from the core business’s sustainable earnings power. Extraordinary income and expenses resulted in a net loss of ¥7.9B. Litigation settlement costs of ¥10.3B were the primary cause of extraordinary losses, while gains on sales of investment securities of ¥3.1B partially offset them, limiting the impact on Net Income. Comprehensive Income of ¥363.1B substantially exceeded Net Income of ¥215.7B, with unrealized valuation factors such as foreign currency translation adjustments of ¥80.8B and valuation differences on securities of ¥56.5B contributing to the result. This divergence indicates that Comprehensive Income was boosted beyond the period’s underlying business earnings power. Accordingly, the difference between Net Income and Comprehensive Income should be considered when evaluating earnings quality. The 22.7% increase in inventories also entails a risk of future valuation losses, making inventory trends worth monitoring from an accrual perspective.

Earnings Forecast and Guidance

The full-year company plan calls for Revenue of ¥4150.0B, Operating Income of ¥415.0B, and Ordinary Income of ¥415.0B. The cumulative Q3 progress rates were 71.5% for Revenue, 70.6% for Operating Income, and 73.2% for Ordinary Income, all below the standard progress rate of 75%. To achieve the full-year plan, Q4 must generate Revenue of ¥1182.1B and Operating Income of ¥121.9B. This corresponds to an Operating Margin of 10.3%, above the cumulative actual result of 9.9%. Recovery in the Chemicals Business’s profit margin and continued strong performance in the Life Sciences Business will be the key focuses for achieving the plan in the second half.

Shareholder Returns

The Q2 dividend was ¥52.00 per share, and the forecast full-year dividend is ¥104.00 per share. The forecast Payout Ratio against forecast full-year EPS of ¥257.70 is approximately 40.4%, below the 60% level generally considered a benchmark for the sustainability of dividends alone. Against cumulative Q3 Net Income attributable to owners of the parent of ¥198.5B, the estimated total annual dividend is approximately ¥103B, providing adequate dividend coverage even on a cumulative earnings basis. Treasury stock increased by ¥95.6B YoY, indicating expanded capital returns in addition to dividends. However, because the treasury stock acquisition amount is not disclosed, the Total Return Ratio is not calculated. The financial flexibility provided by the net cash position supports continued earnings-linked dividend payments.

Risk Factors

1. Declining revenue and earnings in the core business: Revenue in the Chemicals Business declined 5.1% YoY, while segment profit declined 12.2% YoY, and its margin also fell by approximately 1pt from the previous year to 12.5%. As the segment makes the largest contribution to consolidated Operating Income, at approximately 68%, trends in demand and changes in its cost structure could significantly affect company-wide performance.

2. Deterioration in working capital efficiency: Inventories increased 22.7% YoY to ¥754.5B, accounting for 13.5% of total assets. Although accounts receivable declined 10.4% YoY to ¥985.7B, improving working capital efficiency in terms of both collections and inventory remains an issue. Attention should be paid to the risk of valuation losses and funds becoming tied up when demand fluctuates.

3. Need for profitability improvements to achieve the full-year plan: Achieving the full-year Operating Income plan requires a Q4 Operating Margin of 10.3%, necessitating an improvement above the cumulative actual result of 9.9%. If recovery in the Chemicals Business’s profit margin is delayed, the downside progress gap against the full-year plan could widen.

Industry Benchmark (Reference; Compiled by the Company)

Industry Benchmark (manufacturing)

Profitability and Returns

Profitability is above the industry median, and the company maintains relatively high earnings power within the manufacturing sector.

Growth and Capital Efficiency

The Revenue Growth Rate is below the industry median, placing the company’s top-line growth at a relatively disadvantageous level within the industry.

※Source: Compiled by the company

Key Points from the Results

1. The Life Sciences Business achieved high growth and significant earnings expansion, with Revenue up +14.6% and segment profit up +66.4%; its margin also improved to 7.2%. This indicates a growing role for the segment within the business portfolio as a structural change that offsets the declines in revenue and earnings in the core Chemicals Business.

2. While the gross margin improved to 28.6%, the increase in selling, general and administrative expenses (+2.8%) exceeded Revenue growth (+0.1%), causing the Operating Margin to decline to 9.9%. The fact that the benefits of cost efficiency improvements were offset by higher selling, general and administrative expenses is a key point regarding the cost structure.

3. Against an Equity Ratio of 65.3% and a net cash financial foundation, the deduction for treasury stock increased by ¥95.6B YoY. While capital returns are expanding, funds are also becoming tied up in working capital due to higher inventories, making capital allocation priorities a key focus going forward.

Theoretical Share Price (Reference Value)

Sensitivity: ¥3,409–¥3,607 at ±1% for the cost of equity, and ¥3,499–¥3,510 at ±0.1 for ω.

Notes:

• Since forecast ROE is below the cost of equity, the theoretical value is below book value per share.
• Net assets as of the end of the quarter are used (there is a timing difference from the full-year forecast).
• Because net assets include non-controlling interests, the theoretical value may be calculated somewhat higher.

(Calculation model: Residual Income Model (Ohlson-type, explicit 5-year fade) / Interest rate reference month: 2026-07 / This is a mechanically calculated value based solely on publicly disclosed data; it is not a forecast of the market share price or a recommendation of any specific investment action, and does not forecast or guarantee future share prices.)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings summary data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the company based on publicly disclosed earnings data. Investment decisions should be made at your own discretion and responsibility, after consulting with a professional as necessary.

---End of Report---